Literature DB >> 18551626

Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice.

Annadora J Bruce-Keller1, Jadwiga Turchan-Cholewo, Eric J Smart, Theresa Geurin, Ashok Chauhan, Rollie Reid, Ruqiang Xu, Avindra Nath, Pamela E Knapp, Kurt F Hauser.   

Abstract

HIV encephalitis (HIVE) is accompanied by brain inflammation, leukocyte infiltration, and glial activation, and HIV patients who abuse opiates are more likely to develop HIVE. To better understand how opiates could alter HIV-related brain inflammation, the expression of astrocyte (GFAP immunoreactivity) and macrophage/microglial (F4/80 or Mac1 immunoreactivity) markers in the striatum, and the percentage of 3-nitrotyrosine (3-NT) positive macrophages/microglia, was determined following a 2-day exposure to morphine (5 mg/kg/day via time-release, subcutaneous implant) and doxycycline in GFAP-driven, doxycycline-inducible HIV-1 Tat transgenic mice. Data show that both morphine and Tat induction via doxycycline increased astrocyte activation, with significant additive increases achieved with combined morphine and doxycycline exposure. By contrast, combined Tat induction and morphine exposure, but neither manipulation alone, significantly increased the proportion of macrophages/microglia present in the striatum of transgenic mice, although morphine exposure was necessary to elevate 3-NT co-detection in Mac1-positive macrophages/microglia. Finally, Tat induction increased the percentage of neurons expressing active caspase-3, and this was even more significantly elevated by co-administration of morphine. In spite of elevations in caspase-3, neuronal TUNEL reactivity was unchanged in all groups, even after 10 days of Tat induction. Importantly, co-administration of naltrexone completely antagonized the effects of morphine. These findings indicate that morphine rapidly and significantly increases the activation of astrocytes and macrophages/microglia in the brains of inducible Tat transgenic mice, supporting the theory that early inflammatory changes in glia could underlie the development of HIVE in opiate-abusing AIDS patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18551626      PMCID: PMC2725184          DOI: 10.1002/glia.20708

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  92 in total

1.  Active caspase-3 expression during postnatal development of rat cerebellum is not systematically or consistently associated with apoptosis.

Authors:  Sowmini Oomman; Velvetlee Finckbone; Janet Dertien; Jennifer Attridge; William Henne; Margarita Medina; Bobbak Mansouri; Hema Singh; Howard Strahlendorf; Jean Strahlendorf
Journal:  J Comp Neurol       Date:  2004-08-16       Impact factor: 3.215

Review 2.  Surviving the kiss of death.

Authors:  Jiang-Yan Yang; David Michod; Joël Walicki; Christian Widmann
Journal:  Biochem Pharmacol       Date:  2004-09-15       Impact factor: 5.858

Review 3.  Exogenous and endogenous opioids as biological response modifiers.

Authors:  D J Carr; M Serou
Journal:  Immunopharmacology       Date:  1995-11

4.  The AIDS dementia complex: II. Neuropathology.

Authors:  B A Navia; E S Cho; C K Petito; R W Price
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422

Review 5.  Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions.

Authors:  Luisa Minghetti; Sergio Visentin; Mario Patrizio; Laura Franchini; Maria Antonietta Ajmone-Cat; Giulio Levi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

6.  Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat.

Authors:  Teresa G D'Aversa; Karl O A Yu; Joan W Berman
Journal:  J Neurovirol       Date:  2004-04       Impact factor: 2.643

7.  Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: Differential involvement of caspase-3 and endonuclease G.

Authors:  Indrapal N Singh; Robin J Goody; Celeste Dean; Nael M Ahmad; Sarah E Lutz; Pamela E Knapp; Avindra Nath; Kurt F Hauser
Journal:  J Neurovirol       Date:  2004-06       Impact factor: 2.643

8.  Comparison of the effects of morphine on locomotor activity, analgesia and primary and protracted physical dependence in six mouse strains.

Authors:  D A Brase; H H Loh; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1977-05       Impact factor: 4.030

9.  Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia.

Authors:  J D Glass; H Fedor; S L Wesselingh; J C McArthur
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

10.  Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients.

Authors:  Linda Chang; Thomas Ernst; Coryse St Hillaire; Katherine Conant
Journal:  Antivir Ther       Date:  2004-06
View more
  93 in total

Review 1.  Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury.

Authors:  Ricky Maung; Kathryn E Medders; Natalia E Sejbuk; Maya K Desai; Rossella Russo; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-29       Impact factor: 4.147

2.  Quantitation of parvalbumin+ neurons and human immunodeficiency virus type 1 (HIV-1) regulatory gene expression in the HIV-1 transgenic rat: effects of vitamin A deficiency and morphine.

Authors:  Shireen Sultana; Huifen Li; Adam Puche; Odell Jones; Joseph L Bryant; Walter Royal
Journal:  J Neurovirol       Date:  2010-02       Impact factor: 2.643

Review 3.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

4.  Morphine affects HIV-induced inflammatory response without influencing viral replication in human monocyte-derived macrophages.

Authors:  Rajnish S Dave
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03

5.  Gene delivery of antioxidant enzymes inhibits human immunodeficiency virus type 1 gp120-induced expression of caspases.

Authors:  J-P Louboutin; L Agrawal; B A S Reyes; E J van Bockstaele; D S Strayer
Journal:  Neuroscience       Date:  2012-04-21       Impact factor: 3.590

Review 6.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

7.  Methamphetamine augment HIV-1 Tat mediated memory deficits by altering the expression of synaptic proteins and neurotrophic factors.

Authors:  Anantha Ram Nookala; Daniel C Schwartz; Nitish S Chaudhari; Alexy Glazyrin; Edward B Stephens; Nancy E J Berman; Anil Kumar
Journal:  Brain Behav Immun       Date:  2018-05-02       Impact factor: 7.217

8.  Chronic central nervous system expression of HIV-1 Tat leads to accelerated rarefaction of neocortical capillaries and loss of red blood cell velocity heterogeneity.

Authors:  Jharon N Silva; Oksana Polesskaya; Helen S Wei; Izad-Yar D Rasheed; Jeffrey M Chamberlain; Christopher Nishimura; Changyong Feng; Stephen Dewhurst
Journal:  Microcirculation       Date:  2014-10       Impact factor: 2.628

9.  Chronic HIV-1 Tat and HIV reduce Rbfox3/NeuN: evidence for sex-related effects.

Authors:  Yun Kyung Hahn; Ruturaj R Masvekar; Ruqiang Xu; Kurt F Hauser; Pamela E Knapp
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

10.  CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice.

Authors:  Nazira El-Hage; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2008-09-25       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.